We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
The Structural Genomics Consortium Oxford is leading a new open-access platform to generate novel high-quality reproducible and renewable antibodies for both established and novel ALS genes and variants.
The Ministry of Health of Brazil and Oxford’s Centre for Immuno-Oncology, part of the Nuffield Department of Medicine, have signed a Letter of Intent establishing a broad collaboration to advance cancer research, innovation and clinical translation. The agreement builds on the UK-Brazil Government Health Partnership signed earlier this year, and reflects a shared commitment to accelerating research that will lead to improvements in cancer care across Brazil.
